2-Aminoquinazoline LRRK2 Inhibitors With Brain-Penetrant Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and other disorders associated with LRRK2 kinase activity are inadequate, as they lack potent and selective inhibitors that can effectively target LRRK2 kinase activity to ameliorate symptoms and progression.
Innovation Solution
Development of 2-aminoquinazoline derivatives that act as selective LRRK2 inhibitors, exhibiting excellent inhibitory activity against LRRK2 kinase, which can be used in pharmaceutical compositions to treat or prevent diseases involving LRRK2 kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative diseases are used, then patients receive standard care, but the treatments lack potent and selective LRRK2 inhibition leading to inadequate therapeutic effect
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of quinazoline derivatives through systematic modification of substituents at positions R1, R2, R3, R4, and R5. This structural parameter optimization enables the compounds to achieve both potent LRRK2 inhibition (IC50 values in low micromolar to nanomolar range) and selective targeting of LRRK2 kinase activity over other kinases, thereby resolving the contradiction between therapeutic efficacy and selectivity
Solution Approach 2:
The patent employs local quality by introducing specific functional groups at defined positions on the quinazoline core structure. For example, particular substituents at R4 and R5 positions provide localized interactions with specific residues in the LRRK2 kinase binding pocket, enabling selective inhibition. This localized structural optimization allows the molecule to achieve high selectivity for LRRK2 while maintaining potent inhibitory activity
2Reliability
If LRRK2 kinase activity is inhibited, then aberrant signaling in neurodegenerative diseases is blocked, but the need for brain penetrant compounds increases complexity to the pharmaceutical formulation
Solution Approach 1:
The patent addresses formulation complexity by optimizing physicochemical parameters of the quinazoline derivatives, including molecular weight, lipophilicity (clogP), and hydrogen bonding capacity. These parameter optimizations enable the compounds to achieve adequate brain penetration through the blood-brain barrier while maintaining selective LRRK2 inhibition, thereby reducing the need for complex formulation strategies
3Reliability
If potent LRRK2 inhibitors are developed, then therapeutic potential for Parkinson's disease and other neurodegenerative disorders is achieved, but the requirement for high manufacturing precision increases production difficulty
Solution Approach 1:
The patent applies segmentation by dividing the synthesis of complex quinazoline derivatives into modular stages: (1) construction of the quinazoline core, (2) introduction of substituents at R1-R5 positions through sequential reactions, and (3) final purification. This segmented approach allows each synthesis step to be optimized independently, achieving high manufacturing precision for potent inhibitors while maintaining practical production feasibility
Data Source
AI summary
The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.